ArticleInterdisciplinary cardiovascular and thoracic surgery2025
The prognostic significance of subcarinal lymph node dissection in esophagectomy for middle and lower thoracic squamous cell carcinoma.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic value of lymphadenectomy after neoadjuvant chemotherapy in esophageal squamous cell carcinoma.General thoracic and cardiovascular surgery · 2026Article
- Clinical-Radiomics Signature Predicts Pathologic Complete Response After Neoadjuvant Therapy in Oesophageal Squamous Cell Carcinoma.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis retrospective study assesses the prognostic value of subcarinal lymph node dissection (SCLND) in esophageal squamous cell carcinoma (ESCC) of the middle and lower thoracic regions.
methodsThe study, conducted at the Fourth Hospital of Hebei Medical University, included 1587 patients with ESCC who underwent radical resection from 2008 to 2014, comprising 204 patients in the non-SCLND group and 1383 patients in the SCLND group. After applying inverse probability of treatment weighting (IPTW) to adjust for confounders, Kaplan-Meier curves, log-rank tests, and Cox regression were used for survival analysis, performed using R.
resultsSCLN metastasis was found in 9.8% of patients. Factors influencing metastasis included pathologic T stage (P < 0.001) and N stage (P < 0.001). SCLN metastasis significantly affected overall survival, with 5-year rates of 49.0% for non-metastatic versus 7.0% for metastatic patients. SCLND improved long-term survival for T3-T4a stage patients but not for T1-T2.
conclusionsDespite a low SCLN metastasis rate, its presence significantly worsens prognosis. SCLND does not significantly improve long-term survival in patients with pathologic T1-T2 tumors, but it may confer a survival benefit in T3-T4a stage disease, supporting individualized surgical decisions regarding lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.